| A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis (NCT05250115) | Pfizer | 2022-05-10 |
| Assessment of Clinical, Biological and Biometrological Paramaters in Adult Subjects Suffering From AD (NCT05639738) | Pierre Fabre Dermo Cosmetique | 2022-03-08 |
| A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area (NCT05226143) | Johnson & Johnson Consumer Inc. (J&JCI) | 2022-02-21 |
| A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359) (NCT05235724) | Sanofi | 2022-02-17 |
| A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries (NCT05214326) | Sanofi | 2022-01-18 |
| A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine (NCT05149313) | Almirall, S.A. | 2021-12-23 |
| Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis (NCT04975438) | GlaxoSmithKline | 2021-11-18 |
| A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants (NCT05094700) | Johnson & Johnson Consumer Inc. (J&JCI) | 2021-10-25 |
| Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis (NCT05641558) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2021-10-18 |
| Long-Term Follow-up Study of FURESTEM-AD in Patients With Atopic Dermatitis(K0106) (NCT07582237) | Kang Stem Biotech Co., Ltd. | 2021-10-05 |
| A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis (NCT04990440) | Janssen Research & Development, LLC | 2021-09-02 |
| Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis (NCT04761978) | University Hospital, Lille | 2021-09-01 |
| Integrative Body-Mind-Spirit Intervention for Families With Children Suffering From Eczema (NCT04617977) | The University of Hong Kong | 2021-08-23 |
| A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis (NCT05014438) | Bristol-Myers Squibb | 2021-08-17 |
| NMF-CsA-Dupi Trial (NCT04878770) | Erasmus Medical Center | 2021-08-16 |
| Results in Real Clinical Practice of Treatment of Moderate-severe Atopic Dermatitis (NCT05078294) | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 2021-08-01 |
| To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis (NCT04684485) | Sun Pharmaceutical Industries Limited | 2021-07-30 |
| China Atopic Dermatitis Registry Study (NCT05023668) | Peking University People's Hospital | 2021-07-28 |
| Safety and Efficacy of FURESTEM-AD Inj. for Moderate to Severe Atopic Dermatitis (AD) (NCT05004324) | Kang Stem Biotech Co., Ltd. | 2021-06-29 |
| A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis (NCT04800315) | Celgene | 2021-05-14 |
| A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (NCT04791319) | Janssen Research & Development, LLC | 2021-05-03 |
| Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis (NCT04823130) | Sanofi | 2021-04-22 |
| A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis (NCT04760314) | Eli Lilly and Company | 2021-03-10 |
| Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis (NCT04718870) | Sanofi | 2021-02-19 |
| A Study of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infants, Toddlers and Children (NCT04740892) | Johnson & Johnson Consumer Inc. (J&JCI) | 2021-01-21 |
| Goat Infant Formula Feeding and Eczema (the GIraFFE Study) (NCT04599946) | Dairy Goat Co-operative (N.Z.) Limited | 2021-01-08 |
| A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD) (NCT04220411) | Arjil Pharmaceuticals LLC | 2020-12-08 |
| Stabilized Whole Rice Bran (SWRB) for Mild to Moderate Atopic Dermatitis (NCT04635072) | RCSI & UCD Malaysia Campus | 2020-09-21 |
| Long-Term Safety Follow-Up Study of SCM-AGH in Subjects Who Participated and Administered SCM-AGH in to Severe Atopic Dermatitis Clinical Trials (NCT04185584) | SCM Lifescience Co., LTD. | 2020-08-25 |
| Moisturizer to Prevent Atopic Dermatitis (NCT03808532) | MYOR Ltd. | 2020-06-01 |
| Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic Dermatitis (NCT04440410) | Kymera Therapeutics, Inc. | 2020-05-28 |
| Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis (NCT04179760) | SCM Lifescience Co., LTD. | 2020-03-24 |
| A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab (NCT04365387) | Galderma R&D | 2020-03-05 |
| Study on the Correlation Between Intestinal Microecology and Allergic Diseases in Children (NCT04938700) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2020-03-01 |
| A Study of LY3471851 in Participants With Eczema (NCT04081350) | Nektar Therapeutics | 2019-12-04 |
| A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants (NCT04135560) | Pfizer | 2019-10-29 |
| A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032 (NCT04086121) | Boehringer Ingelheim | 2019-09-24 |
| Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2) (NCT04011215) | Murdoch Childrens Research Institute | 2019-09-23 |
| Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation (NCT04065633) | Pfizer | 2019-07-18 |
| Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) (NCT03992417) | Sanofi | 2019-06-11 |
| Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis (NCT03868098) | Innovaderm Research Inc. | 2019-05-21 |
| Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY) (NCT03849716) | Sanofi | 2019-04-05 |
| Study to Evaluate the Use of RHT-3201 in SCORAD Reduction in Young Patients With Atopic Dermatitis (NCT03907228) | IlDong Pharmaceutical Co Ltd | 2019-03-15 |
| Improving Therapeutic Patient Education for Atopic Dermatitis: Evaluation of a Parent Handbook (NCT03722706) | Boston Children's Hospital | 2019-02-26 |
| A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated (NCT03822832) | Boehringer Ingelheim | 2019-02-12 |
| Study to Evaluate ASN008 Topical Gel (TG) (NCT03798561) | Asana BioSciences | 2019-01-14 |
| Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy (NCT05674695) | Fundación Academia Española de Dermatología | 2019-01-01 |
| A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis (NCT03754309) | Kymab Limited | 2018-12-13 |
| A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis (NCT03750643) | Eli Lilly and Company | 2018-11-29 |
| Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy (NCT03720470) | Pfizer | 2018-10-29 |
| Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis (NCT03568136) | GWT-TUD GmbH | 2018-09-18 |
| Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation) (NCT03672383) | Bayer | 2018-09-17 |
| Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842. (NCT03634345) | Pfizer | 2018-09-12 |
| Effect of Benralizumab in Atopic Dermatitis (NCT03563066) | McMaster University | 2018-09-04 |
| Effect of Different Skin Creams on TEWL (NCT03663673) | Stanford University | 2018-09-01 |
| Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (NCT03575871) | Pfizer | 2018-06-29 |
| Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects (NCT03627767) | Pfizer | 2018-06-11 |
| Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) (NCT03428646) | Regeneron Pharmaceuticals | 2018-04-06 |
| Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (NCT03422822) | Pfizer | 2018-03-08 |
| Efficacy Of Antenatal Maternal Supplementation With GOS/Inulin Prebiotics On Atopic Dermatitis Prevalence In High-Risk One-Year-Old Children (NCT03183440) | Nantes University Hospital | 2018-02-13 |
| Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (NCT03349060) | Pfizer | 2017-12-07 |
| Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL) (NCT03346434) | Regeneron Pharmaceuticals | 2017-11-30 |
| Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) (NCT03345914) | Regeneron Pharmaceuticals | 2017-11-17 |
| Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis (NCT03233529) | Pfizer | 2017-07-31 |
| Topical NanoDox® for Atopic Dermatitis (NCT02910011) | University of Florida | 2017-05-18 |
| A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis (NCT03139981) | Asana BioSciences | 2017-04-12 |
| A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis (NCT03096223) | Kyowa Kirin Co., Ltd. | 2017-04-10 |
| Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis (NCT03054428) | Regeneron Pharmaceuticals | 2017-03-21 |
| Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis (NCT03055195) | GlaxoSmithKline | 2017-03-21 |
| In-Use Test With a Cosmetic Product (NCT03252730) | Dr. August Wolff GmbH & Co. KG Arzneimittel | 2017-01-30 |
| Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis: Randomized, Double-blind Controlled Trial (NCT03042624) | University of Milan | 2017-01-24 |
| Atopic Dermatitis in Atopy Predisposed Infants (NCT02906475) | HiPP GmbH & Co. Vertrieb KG | 2016-11-01 |
| Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients (NCT02900131) | Kyung Hee University Hospital at Gangdong | 2016-09-19 |
| A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists (NCT02916888) | Yale University | 2016-09-01 |
| Animal Allergy in Korean Veterinary Researcher (NCT02866864) | Gachon University Gil Medical Center | 2016-08-24 |
| First in Human of Single and Multiple Doses of MOR106 (NCT02739009) | Lakefront Biotherapeutics NV | 2016-04-01 |
| Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis (NCT02732314) | Procter & Gamble Beauty | 2016-03-01 |
| Topical Steroid Formulation and Wet Wraps (NCT02680301) | Seton Healthcare Family | 2016-03-01 |
| Efficacy and Tolerability of HAT1 in Patients With Moderate to Severe Atopic Dermatitis (NCT03059693) | Haus Bioceuticals | 2016-02-29 |
| A Multicenter Randomized Control Trial in Children With Moderate to Severe Atopic Dermatitis to Assess the Benefit of a Nurse-led One-to-one Education Program in Addition to Standard Care Compared to Standard Care Alone on the Long Term Control of Disease Severity at 6 Months (NCT02634905) | Nantes University Hospital | 2016-02-01 |
| An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis (NCT02655679) | Vitae Pharmaceuticals, Inc. | 2015-12-15 |
| An Observational Study Investigating the Treatment Satisfaction of Atopic Dermatitis Patients Who Have Switched to Ointment (W/O Emulsion) Formulation of Very Strong Class Topical Corticosteroids (NCT02627989) | LEO Pharma | 2015-12-10 |
| A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD) (NCT02564055) | GlaxoSmithKline | 2015-12-01 |
| Skin Irritation Study of GSK2894512 Cream (NCT02637206) | GlaxoSmithKline | 2015-10-27 |
| A Pharmacokinetic Study to Evaluate BBI-5000 Capsules and Food Effect in Healthy Adult Subjects (NCT02590289) | Fresh Tracks Therapeutics, Inc. | 2015-10-01 |
| Bathing Additives in Pediatric Atopic Dermatitis (NCT02582788) | Mayo Clinic | 2015-10-01 |
| Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis (NCT02595008) | Sun Pharmaceutical Industries, Inc. | 2015-08-28 |
| Does Treatment With Montelukast Improve Symptoms of Atopic Dermatitis in Children? (NCT02534467) | Murdoch Childrens Research Institute | 2015-07-09 |
| A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream (NCT02411162) | Stiefel, a GSK Company | 2015-07-07 |
| Pharmacokinetic Study of Topical GSK2894512 Cream (NCT02466152) | GlaxoSmithKline | 2015-05-28 |
| Study of Autologous Total Immunoglobulin G Therapy for Atopic Dermatitis (NCT02835170) | Ajou University School of Medicine | 2015-04-02 |
| The Effectiveness of Tailored Messages on the Usage of Emollient in Patients With Atopic Dermatitis (NCT02343861) | Seoul National University Hospital | 2015-01-01 |
| A Study to Evaluate Use of Induced Skin Blisters in Adult Participants With Atopic Dermatitis, Allergic Asthma and Atopic Healthy Participants (NCT02343783) | Janssen Research & Development, LLC | 2015-01-01 |
| A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal (NCT02317276) | University of California, San Francisco | 2014-12-01 |
| Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis (NCT02286700) | NeoStrata Company, Inc. | 2014-11-01 |
| Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (NCT02277743) | Regeneron Pharmaceuticals | 2014-10-01 |
| Wool Clothing for the Management of Childhood Atopic Dermatitis (NCT02534428) | Murdoch Childrens Research Institute | 2014-06-01 |
| ADRN Barrier/Immunoprofiling Exploratory Pilot Study (NCT02115399) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-04-01 |
| Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis (NCT02118792) | Pfizer | 2014-03-01 |
| Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis (NCT02118766) | Pfizer | 2014-03-01 |